BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28865741)

  • 1. Long-term outcomes of inappropriate antibiotic therapy for upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a retrospective cohort study.
    Greenhouse I; Babushkin F; Finn T; Shimoni Z; Aliman M; Ben-Ami R; Cohen R
    Diagn Microbiol Infect Dis; 2017 Nov; 89(3):222-229. PubMed ID: 28865741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
    Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
    Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae-Related Urinary Tract Infection in Kidney Transplant Recipients: Risk Factors, Treatment, and Long-Term Outcome.
    Brakemeier S; Taxeidi SI; Zukunft B; Schmidt D; Gaedeke J; Dürr M; Hansen S; Budde K
    Transplant Proc; 2017 Oct; 49(8):1757-1765. PubMed ID: 28923621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Asakura T; Ikeda M; Nakamura A; Kodera S
    Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
    Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
    Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram.
    García-Tello A; Gimbernat H; Redondo C; Meilán E; Arana DM; Cacho J; Dorado JF; Angulo JC
    Scand J Urol; 2018 Feb; 52(1):70-75. PubMed ID: 28893132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
    Kim SA; Altshuler J; Paris D; Fedorenko M
    Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-spectrum β-lactamase-producing Enterobacteriaceae, national study of antimicrobial treatment for pediatric urinary tract infection.
    Lagree M; Bontemps S; Dessein R; Angoulvant F; Madhi F; Martinot A; Cohen R; Dubos F;
    Med Mal Infect; 2018 May; 48(3):193-201. PubMed ID: 29449049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: A French prospective multicenter study.
    Madhi F; Jung C; Timsit S; Levy C; Biscardi S; Lorrot M; Grimprel E; Hees L; Craiu I; Galerne A; Dubos F; Cixous E; Hentgen V; Béchet S; ; Bonacorsi S; Cohen R
    PLoS One; 2018; 13(1):e0190910. PubMed ID: 29370234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing and nonproducing bacteria: a comparative study.
    Dayan N; Dabbah H; Weissman I; Aga I; Even L; Glikman D
    J Pediatr; 2013 Nov; 163(5):1417-21. PubMed ID: 23919903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence.
    Pilmis B; Scemla A; Join-Lambert O; Mamzer MF; Lortholary O; Legendre C; Zahar JR
    Infect Dis (Lond); 2015; 47(10):714-8. PubMed ID: 26024285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
    de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
    Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.
    Espinar MJ; Miranda IM; Costa-de-Oliveira S; Rocha R; Rodrigues AG; Pina-Vaz C
    PLoS One; 2015; 10(8):e0134737. PubMed ID: 26237422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in a medical center in Taiwan: a prospective cohort study.
    Kung CH; Ku WW; Lee CH; Fung CP; Kuo SC; Chen TL; Lee YT
    J Microbiol Immunol Infect; 2015 Apr; 48(2):168-74. PubMed ID: 24064292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation.
    Brizendine KD; Richter SS; Cober ED; van Duin D
    Antimicrob Agents Chemother; 2015 Jan; 59(1):553-7. PubMed ID: 25385105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria.
    Briongos-Figuero LS; Gómez-Traveso T; Bachiller-Luque P; Domínguez-Gil González M; Gómez-Nieto A; Palacios-Martín T; González-Sagrado M; Dueñas-Laita A; Pérez-Castrillón JL
    Int J Clin Pract; 2012 Sep; 66(9):891-6. PubMed ID: 22897466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of non-carbapenem antibiotics to treat severe extended-spectrum β-lactamase-producing Enterobacteriaceae infections in intensive care unit patients.
    Luyt CE; Faure M; Bonnet I; Besset S; Huang F; Junot H; Hékimian G; Schmidt M; Bréchot N; Combes A; Aubry A; Mayaux J; Chastre J
    Int J Antimicrob Agents; 2019 May; 53(5):547-552. PubMed ID: 30742956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urinary Tract Infections Caused by Community-Acquired Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in a Level III Hospital - A Retrospective Study].
    Simões A; Lima M; Brett A; Queiroz C; Chaves C; Oliveira H; Januário L; Rodrigues F
    Acta Med Port; 2020 Jul; 33(7-8):466-474. PubMed ID: 31962058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.